In previous studies, MET amplification was defined based on the MET/CEP7 ratio, using FISH analysis, and it was found to occur in approximately 5% of patients with NSCLC or gastric adenocarcinoma, with a cut-off value of MET/CEP > 2.2 [16]. This evidence concerns the gene MET and gastric adenocarcinoma.